BioSight
Companies
Lexeo Therapeutics, Inc. logo

LXEO

NASDAQNEW YORK, NY
Lexeo Therapeutics, Inc.

Lexeo Therapeutics develops drug candidates for neurological and neuropsychiatric diseases, with two lead programs—LX2006 and LX2020—currently in clinical development. Lexeo is using gene therapy and other molecular approaches to treat conditions in the central nervous system. Lexeo remains in the clinical-stage of development, working toward regulatory submissions and clinical trial initiation for its product candidates.

Price history not yet available for LXEO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar